KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Gross Margin (2016 - 2025)

Historic Gross Margin for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to 90.13%.

  • Supernus Pharmaceuticals' Gross Margin rose 1400.0% to 90.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.61%, marking a year-over-year decrease of 4400.0%. This contributed to the annual value of 88.23% for FY2024, which is 20200.0% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Gross Margin is 90.13%, which was up 1400.0% from 89.83% recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Gross Margin ranged from a high of 90.13% in Q3 2025 and a low of 82.29% during Q2 2021
  • Over the past 5 years, Supernus Pharmaceuticals' median Gross Margin value was 88.06% (recorded in 2023), while the average stood at 87.52%.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Gross Margin plummeted by -110900bps in 2021, and later surged by 56800bps in 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Gross Margin (Quarter) stood at 89.32% in 2021, then fell by -3bps to 86.28% in 2022, then increased by 2bps to 88.06% in 2023, then fell by -3bps to 85.01% in 2024, then rose by 6bps to 90.13% in 2025.
  • Its last three reported values are 90.13% in Q3 2025, 89.83% for Q2 2025, and 89.48% during Q1 2025.